A deterministic snapshot of the global clinical-trial landscape — every figure reproducible from the ClinicaLister knowledge graph.
Registered in the past 7 days.
Trials that moved to a new overall status.
Terminations, withdrawals and suspensions — with the sponsor's stated reason.
\<75% participation
studdy stopped because of patient recruitment issues
recruitment difficulties
Terminated EU portion of trial and utilized US interim analysis data to support marketing application instead. Closure was not due to safety concerns.
Recruitment difficulties due to more attractive competing studies.
Low accrual
Due to the clinical hold, the study was terminated prior to completion, and the Sponsor subsequently determined that the study would not be reopened.
Inadequate patient enrollment
The 2020-2022 Covid-19 pandemic ended this study before completion
Changes in the study staff's role and clinic commitments
Clinical stage asset and the sponsorship have been acquired by Myopharm Limited.
36 approvals month-to-date.
| Sponsor | Drug | Approved |
|---|---|---|
| MERCK SHARP AND DOHME LLC | ENLICITIDE CHLORIDE | 2026-07-16 |
| MERCK SHARP AND DOHME LLC | ENLICITIDE | 2026-07-16 |
| HETERO LABS LTD V | AFATINIB DIMALEATE | 2026-07-14 |
| APOTEX | AFATINIB DIMALEATE | 2026-07-14 |
| CELCUITY INC.. | GEDATOLISIB | 2026-07-14 |
| ANTHEA PHARMA | PROPOFOL | 2026-07-14 |
| TEVA PHARMS USA | ELTROMBOPAG OLAMINE | 2026-07-13 |
| SHANDONG | BRIVARACETAM | 2026-07-13 |
| UNICHEM | ALPRAZOLAM | 2026-07-13 |
7.8% of the last year's EMA authorisations were conditional.
None authorised this period.
1 new · 0 resolved · 105 currently active.
| Newly reported shortage | Posted |
|---|---|
| Tobramycin Sulfate Injection | 2026-07-17 |
Most new trials this week.
Industry sponsors, new trials · trailing 28 days.
New links where the molecule is the studied intervention.
FDA device clearance data is current; MAUDE adverse-event and recall feeds lag ~1-2 months.
Whole-corpus totals and rankings, recomputed every week.
Monthly new registrations across ClinicalTrials.gov. Puts the weekly count in context.
By linked trials (MONDO rollup).
Among the 65,278 trials with a mapped site location — not the whole corpus.
| Sponsor | Trials |
|---|---|
| Cairo University | 4,739 |
| Assiut University | 4,705 |
| GlaxoSmithKline | 3,620 |
| National Cancer Institute (NCI) | 3,549 |
| Assistance Publique - Hôpitaux de Paris | 3,516 |
| AstraZeneca | 3,460 |
| Pfizer | 3,285 |
| Mayo Clinic | 3,219 |
| M.D. Anderson Cancer Center | 3,010 |
| Novartis Pharmaceuticals | 2,674 |
| National Taiwan University Hospital | 2,577 |
| Massachusetts General Hospital | 2,548 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2,436 |
| Boehringer Ingelheim | 2,282 |
| University of California, San Francisco | 2,143 |
| Stanford University | 2,136 |
| Merck Sharp & Dohme LLC | 2,134 |
| Hoffmann-La Roche | 2,078 |
| Riphah International University | 2,075 |
| Eli Lilly and Company | 2,070 |
| Duke University | 2,042 |
| Memorial Sloan Kettering Cancer Center | 1,942 |
| Seoul National University Hospital | 1,881 |
| Ain Shams University | 1,848 |
| Hospices Civils de Lyon | 1,830 |
| Condition | Trials |
|---|---|
| breast cancer | 11,756 |
| obesity disorder | 9,504 |
| type 2 diabetes mellitus | 9,103 |
| chronic pain syndrome | 8,771 |
| cancer | 8,191 |
| HIV infectious disease | 8,189 |
| COVID-19 | 7,634 |
| non-small cell lung carcinoma | 6,329 |
| diabetes mellitus | 6,111 |
| hypertensive disorder | 6,108 |
| colorectal cancer | 5,975 |
| cerebrovascular disorder | 5,972 |
| coronary artery disorder | 5,920 |
| prostate cancer | 5,822 |
| depressive disorder | 5,803 |
| cardiovascular disorder | 5,582 |
| heart failure | 4,874 |
| anxiety disorder | 4,828 |
| injury | 4,458 |
| Parkinson disease | 4,413 |
| cognitive disorder | 4,139 |
| asthma | 4,115 |
| lung cancer | 4,052 |
| benign essential hypertension | 3,866 |
| neuralgia | 3,816 |
| Molecule | Trials |
|---|---|
| carboplatin | 7,124 |
| paclitaxel | 5,396 |
| isoniazid | 5,296 |
| prednisolone | 5,216 |
| cyclophosphamide | 5,096 |
| ropivacaine | 4,821 |
| dexamethasone | 4,771 |
| bevacizumab | 4,560 |
| cisplatin | 4,445 |
| lidocaine | 3,580 |
| aspirin | 3,338 |
| gemcitabine | 3,166 |
| bupivacaine | 3,089 |
| desoxycorticosterone acetate | 2,979 |
| pembrolizumab | 2,958 |
| sitagliptin and metformin hydrochloride | 2,949 |
| metformin | 2,945 |
| rituximab | 2,919 |
| meprednisone | 2,850 |
| dapagliflozin metformin hydrochloride | 2,788 |
| sitagliptin metformin hydrochloride | 2,759 |
| docetaxel | 2,751 |
| linagliptin and metformin hydrochloride | 2,746 |
| fluorouracil | 2,691 |
| alogliptin and metformin hydrochloride | 2,688 |
Standing competitive & regulatory landscape — who is developing what, at which stage, and which drugs are about to lose exclusivity.
Active trials by the most prolific industry sponsors, split by phase.
| Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|
| GlaxoSmithKline | 1,091 | 861 | 890 |
| AstraZeneca | 1,016 | 550 | 800 |
| Pfizer | 1,171 | 709 | 652 |
| Novartis Pharmaceuticals | 508 | 834 | 734 |
| Boehringer Ingelheim | 1,065 | 322 | 399 |
| Merck Sharp & Dohme LLC | 697 | 549 | 737 |
| Hoffmann-La Roche | 491 | 480 | 567 |
| Eli Lilly and Company | 825 | 535 | 548 |
FDA drugs whose exclusivity expires soon (distinct substances).
| Drug (losing exclusivity < 6mo) | Expires |
|---|---|
| Iohexol | 2026-07-26 |
| Alogliptin Benzoate; Metformin Hydrochloride | 2026-07-27 |
| Alogliptin Benzoate | 2026-07-27 |
| Pexidartinib Hydrochloride | 2026-08-02 |
| Octreotide Acetate | 2026-08-02 |
| Fedratinib Hydrochloride | 2026-08-16 |
| Valbenazine Tosylate | 2026-08-18 |
| Gallium Ga-68 Edotreotide | 2026-08-21 |
| Cobicistat | 2026-08-22 |
| Difelikefalin Acetate | 2026-08-23 |
| Ledipasvir; Sofosbuvir | 2026-08-28 |
| Sofosbuvir | 2026-08-28 |
| Citalopram Hydrobromide | 2026-09-16 |
| Phentolamine Mesylate | 2026-09-25 |
| Atogepant | 2026-09-28 |
FDA drugs carrying each designation.
Molecules most often used as the comparator arm (the standard to beat).
Every figure is a deterministic SQL aggregate over the ClinicaLister knowledge graph as of the report date. No figure is AI-generated or estimated; each is reproducible and traceable to its public source.
Sources: ClinicalTrials.gov · EU CTIS · openFDA (drugs, devices, shortages) · EMA · MONDO disease ontology · GSRS · GUDID · Europe PMC / PubMed
Every figure above is a deterministic aggregate over the ClinicaLister knowledge graph — and one click deep in the product, with a source behind each claim.
Machine-readable: download this edition as JSON above, or query the full archive programmatically via the public get_public_report_snapshots endpoint.